An Overview of the Zantac Recall and FDA Investigation Into NDMA Contaminant
In recent months, the Food and Drug Administration (FDA) has requested that all over-the-counter ranitidine drugs, such as Zantac, be removed from the market. This comes during an ongoing investigation of a contaminant known as N-Nitrosodimethylamine, or NDMA. Here, the Baltimore product liability attorneys at The Law Office of Evan K. Thalenberg, P.A. discuss the impacts that NDMA can have on consumers who have taken Zantac, and how to move forward with medical care and legal action as needed.
Ingestion of NDMA Can Lead to Severe Health Problems
NDMA is a chemical found in both industrial and natural processes, and through recent investigation, has been found to pose an unacceptable risk to humans when ingested in excess. NDMA is classified as a probable carcinogen to humans, meaning that according to the Environmental Protection Agency, NDMA may have carcinogenic effects by modifying the DNA of individuals. Additionally, the health effects of overexposure to NDMA include jaundice, nausea, fever, vomiting, abdominal cramps and dizziness, and possible reduced function of the kidney and lungs. Included in ranitidine drug Zantac, consumers are urged to rid their medicine cabinets of Zantac immediately and contact healthcare professionals if needed.
Zantac Poses A Risk to Public Health
The investigation into Zantac and other ranitidine drugs began in 2019, when members of the FDA and outside companies discovered the potentially harmful effects of NDMA to the human body. In addition to the current issues of NDMA in new Zantac products, investigations found that the impurity in some ranitidine products increased over time, leading to unacceptable levels for customers, especially when exposed to higher temperatures. In response to these discoveries, the FDA has requested that all over-the-counter ranitidine products be removed from the market, and customers that currently have access to ranitidine drugs such as Zantac dispose of the medications and do not repurchase. As the coronavirus pandemic continues to plague the country, medication take-back locations may not be open. The FDA has requested that customers follow the specific disposal instructions on their Zantac packages, and seek alternative medications as the investigation continues.
Additional Companies Have Been Required to Remove Their Products Following Zantac Recall
After the initial recall of Zantac from the market in early April 2020, companies including Apotex, Amneal, Marksans, Lupin and Teva for extended release (ER) metformin drugs. As the investigation into NDMA and its effects continues, companies are likely to see recalls and deeper investigation into the components of these drugs. As companies supplying medications to a large number of individuals, pharmaceutical companies including Sanofi, the manufacturer of Zantac, should be aware of the potential effects their products can have on customers, and how these chemicals may negatively impact their short and long-term health. Negligence on the part of these companies is unacceptable, and consumers have a right to speak out about the effects these drugs have had on them or their loved ones.
Speak With Product Liability Attorneys at The Law Office of Evan K. Thalenberg, P.A.
As a firm that specializes in product liability cases, the qualified and compassionate team at The Law Office of Evan K. Thalenberg, P.A. understands the overwhelming sense of frustration and anger many victims feel. The very medications that were supposed to help them in day-to-day life have harmed them, and many consumers are now fearful of how this will impact them physically, emotionally and financially. At the Law Office of Evan K. Thalenberg, P.A., we work tirelessly to fight for the rights of victims of these large pharmaceutical companies, getting them the compensation and voice they deserve. To learn more about how our qualified medical malpractice attorneys can help you, contact our Baltimore office today.